What is Dermlab?
Dermlab, operating under the broader DermPathGroup umbrella, is a prominent provider of dermatopathology services. Formed through the strategic merger of SkinDx and DermLab, the company leverages a state-of-the-art laboratory in Birmingham, AL. Its extensive team comprises over 240 subspecialty expert pathologists, including 14 board-certified dermatopathologists, enabling comprehensive anatomic, clinical, and molecular pathology services. Dermlab is dedicated to delivering precise and prompt diagnostic insights to dermatologists and healthcare providers, aiming to elevate patient outcomes through collaborative efforts and advanced technological integration. The company's mission is to serve as a dependable diagnostic partner, enhancing the standard of care for individuals with skin conditions across 14 states.
How much funding has Dermlab raised?
Dermlab has raised a total of $987K across 2 funding rounds:
Debt
$350K
Debt
$637K
Debt (2020): $350K with participation from PPP
Debt (2021): $637K led by PPP
Key Investors in Dermlab
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Dermlab?
The recent major strategic investment signifies a pivotal moment for Dermlab, positioning it for accelerated expansion and enhanced service delivery. This capital infusion is expected to fuel further technological advancements in their diagnostic capabilities and potentially broaden their geographic reach. As a company focused on specialized pathology services, Dermlab is likely to reinvest in its research and development, aiming to solidify its leadership in dermatopathology and maintain its competitive edge in a dynamic healthcare market. The enterprise-level funding suggests a focus on scaling operations and potentially exploring new service lines or strategic partnerships to further its mission of improving patient care.
See full Dermlab company page
